Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse trancripatse inhibitor" backbone of highly active antiretroviral therapy in resource limited settings.
about
Proviral HIV-genome-wide and pol-gene specific zinc finger nucleases: usability for targeted HIV gene therapy.Theoretical basis for reducing time-lines to the determination of positive Mycobacterium tuberculosis cultures using thymidylate kinase (TMK) assaysPharmacogenetics and rational drug use around the world.
P2860
Harnessing pharmacogenomics to tackle resistance to the "nucleoside reverse trancripatse inhibitor" backbone of highly active antiretroviral therapy in resource limited settings.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Harnessing pharmacogenomics to ...... in resource limited settings.
@en
Harnessing pharmacogenomics to ...... in resource limited settings.
@nl
type
label
Harnessing pharmacogenomics to ...... in resource limited settings.
@en
Harnessing pharmacogenomics to ...... in resource limited settings.
@nl
prefLabel
Harnessing pharmacogenomics to ...... in resource limited settings.
@en
Harnessing pharmacogenomics to ...... in resource limited settings.
@nl
P2093
P2860
P1476
Harnessing pharmacogenomics to ...... in resource limited settings.
@en
P2093
Henry Kajumbula
Misaki Wayengera
Wilson Byarugaba
P2860
P356
10.2174/1874613600802010078
P577
2008-11-05T00:00:00Z